Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
BackgroundRandomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.ObjectivesThis work aimed to assess the long-term effectiv...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1285972/full |
| _version_ | 1797391228607660032 |
|---|---|
| author | Jianfeng Zheng Jianfeng Zheng Wenjuan Chen Wenjuan Chen Xuemei Yi Xuemei Yi Ning Yu Ning Yu Yangfeng Ding Yangfeng Ding Yunlu Gao Yunlu Gao |
| author_facet | Jianfeng Zheng Jianfeng Zheng Wenjuan Chen Wenjuan Chen Xuemei Yi Xuemei Yi Ning Yu Ning Yu Yangfeng Ding Yangfeng Ding Yunlu Gao Yunlu Gao |
| author_sort | Jianfeng Zheng |
| collection | DOAJ |
| description | BackgroundRandomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.ObjectivesThis work aimed to assess the long-term effectiveness of guselkumab in actual clinical practice in China.MethodsA retrospective study was performed for plaque psoriasis cases administered guselkumab in Shanghai Skin Disease Hospital between January 2020 and September 2022.ResultsA total of 37 patients were included (29 men, 78.4%), with a mean follow-up period of 72.3 ± 26.7 weeks (range of 12–108 weeks). At baseline, clinical examination revealed a mean PASI of 12.3 ± 7.1, a mean BSA of 17.1 ± 18.1, and a mean DLQI of 7.7 ± 4.3. Twenty-two (62.9%) and 17 (48.6%) cases achieved PASI 90 and PASI 100 responses at week 28. From weeks 60 to 92, >80% of cases achieved PASI 90 and PASI 100 responses. Regarding safety, no cases of serious AEs were recorded. A total of nine cases (24.3%) had different abnormal results in HBV markers, and two were T-SPOT positive. There was no hepatitis B virus or tuberculosis outbreak in these patients.ConclusionThis real-life study confirmed the long-term efficacy and safety of guselkumab in daily clinical practice. |
| first_indexed | 2024-03-08T23:29:52Z |
| format | Article |
| id | doaj.art-79b6784b951545c1869be5d7d5820224 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-08T23:29:52Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-79b6784b951545c1869be5d7d58202242023-12-14T15:21:49ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-12-011010.3389/fmed.2023.12859721285972Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasisJianfeng Zheng0Jianfeng Zheng1Wenjuan Chen2Wenjuan Chen3Xuemei Yi4Xuemei Yi5Ning Yu6Ning Yu7Yangfeng Ding8Yangfeng Ding9Yunlu Gao10Yunlu Gao11Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, ChinaInstitute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, ChinaInstitute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, ChinaInstitute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, ChinaInstitute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, ChinaInstitute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, ChinaInstitute of Psoriasis, Tongji University School of Medicine, Shanghai, ChinaBackgroundRandomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.ObjectivesThis work aimed to assess the long-term effectiveness of guselkumab in actual clinical practice in China.MethodsA retrospective study was performed for plaque psoriasis cases administered guselkumab in Shanghai Skin Disease Hospital between January 2020 and September 2022.ResultsA total of 37 patients were included (29 men, 78.4%), with a mean follow-up period of 72.3 ± 26.7 weeks (range of 12–108 weeks). At baseline, clinical examination revealed a mean PASI of 12.3 ± 7.1, a mean BSA of 17.1 ± 18.1, and a mean DLQI of 7.7 ± 4.3. Twenty-two (62.9%) and 17 (48.6%) cases achieved PASI 90 and PASI 100 responses at week 28. From weeks 60 to 92, >80% of cases achieved PASI 90 and PASI 100 responses. Regarding safety, no cases of serious AEs were recorded. A total of nine cases (24.3%) had different abnormal results in HBV markers, and two were T-SPOT positive. There was no hepatitis B virus or tuberculosis outbreak in these patients.ConclusionThis real-life study confirmed the long-term efficacy and safety of guselkumab in daily clinical practice.https://www.frontiersin.org/articles/10.3389/fmed.2023.1285972/fullChinese patientsefficacyguselkumabplaque psoriasisreal-lifesafety |
| spellingShingle | Jianfeng Zheng Jianfeng Zheng Wenjuan Chen Wenjuan Chen Xuemei Yi Xuemei Yi Ning Yu Ning Yu Yangfeng Ding Yangfeng Ding Yunlu Gao Yunlu Gao Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis Frontiers in Medicine Chinese patients efficacy guselkumab plaque psoriasis real-life safety |
| title | Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis |
| title_full | Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis |
| title_fullStr | Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis |
| title_full_unstemmed | Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis |
| title_short | Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis |
| title_sort | long term efficacy and safety of guselkumab in chinese patients with moderate to severe plaque psoriasis |
| topic | Chinese patients efficacy guselkumab plaque psoriasis real-life safety |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1285972/full |
| work_keys_str_mv | AT jianfengzheng longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT jianfengzheng longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT wenjuanchen longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT wenjuanchen longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT xuemeiyi longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT xuemeiyi longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT ningyu longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT ningyu longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT yangfengding longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT yangfengding longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT yunlugao longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis AT yunlugao longtermefficacyandsafetyofguselkumabinchinesepatientswithmoderatetosevereplaquepsoriasis |